Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ketorolac
Drug ID BADD_D01232
Description Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution.[L6358][L6508][L11055][L3674][L11070] It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis.[L6520] Impressively, ketorolac has a similar efficacy to standard doses of morphine and meperidine making it a useful opioid sparing agent.[L6511]
Indications and Usage Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and has antipyretic, analgesic and anti-inflammatory properties.[A176131] It is indicated for short term management of acute pain that requires the calibre of pain management offered by opioids.[L3674] Clinicians may choose to initiate ketorolac to manage post-operative pain, spinal and soft tissue pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, menstrual disorders and headaches among other ailments.[L6520] Regardless of the etiology of pain, patients should use the lowest possible dose, and avoid using ketorolac for an extended period of time (ideally ≤ 5 days).[L3674] A benefit of choosing ketorolac over other analgesics with similar potency is that that there does not appear to be a risk of dependence or tolerance with ketorolac use.[A176131]
Marketing Status approved
ATC Code M01AB15; S01BC05
DrugBank ID DB00465
KEGG ID D08104
MeSH ID D020910
PubChem ID 3826
TTD Drug ID D0D9JW
NDC Product Code Not Available
UNII YZI5105V0L
Synonyms Ketorolac
Chemical Information
Molecular Formula C15H13NO3
CAS Registry Number 74103-06-3
SMILES C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.007--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 10.01.01.006; 11.07.01.006--
Tremor17.01.06.002--
Ulcer08.03.06.001--Not Available
Unresponsive to stimuli17.02.05.0310.000097%Not Available
Urinary retention20.02.02.011--
Urticaria23.04.02.001; 10.01.06.0010.001611%
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
Vasculitis24.12.04.027; 10.02.02.006--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.0070.001320%
Visual impairment06.02.10.0130.000543%Not Available
Vomiting07.01.07.0030.001630%
Weight increased13.15.01.006--
Wheezing22.03.01.0090.000378%
Tubulointerstitial nephritis20.05.02.002--Not Available
Hypoacusis04.02.01.006--
General physical health deterioration08.01.03.018--Not Available
Post procedural haemorrhage24.07.01.014; 12.02.05.004--
Wound haemorrhage24.07.01.029; 12.01.08.017--Not Available
Rhinalgia22.12.03.020--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Conjunctival hyperaemia06.04.01.004--Not Available
Ear discomfort04.03.01.0050.000330%Not Available
Eye pruritus06.04.05.0060.000213%Not Available
Nasal discomfort22.12.03.0120.003794%Not Available
Protein urine present13.13.02.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Corneal thinning06.06.03.009--Not Available
Haemorrhage24.07.01.0020.000456%Not Available
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages